Co-Authors
This is a "connection" page, showing publications co-authored by Danielle Porter and Joy Feng.
Connection Strength
0.800
-
Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?" Antimicrob Agents Chemother. 2021 03 18; 65(4).
Score: 0.234
-
Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. Antimicrob Agents Chemother. 2021 01 20; 65(2).
Score: 0.231
-
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
Score: 0.060
-
Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem. 2020 11 20; 295(47):16156-16165.
Score: 0.057
-
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
Score: 0.056
-
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020 05 15; 295(20):6785-6797.
Score: 0.055
-
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020 04 10; 295(15):4773-4779.
Score: 0.054
-
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
Score: 0.054